These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16901285)

  • 21. Hepatitis C treatment: shorter and better?
    Araújo ES; Courtouké C; Barone AA
    Braz J Infect Dis; 2007 Feb; 11(1):118-24. PubMed ID: 17625740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection.
    Ackerman Z; Pappo O; Ben-Dov IZ
    J Med Virol; 2011 Jul; 83(7):1262-8. PubMed ID: 21567428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
    Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral lymphocyte subsets in chronic hepatitis C: Effects of 12 weeks of antiviral treatment with interferon-alpha plus ribavirin.
    Oliveira IS; Carvalho LP; Schinoni MI; Paraná R; Atta AM; Atta ML
    Microb Pathog; 2016 Feb; 91():155-60. PubMed ID: 26718098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    Zhang L; Han F; Zhang D; Dou XG
    Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
    Castelain S; Bonte D; Penin F; François C; Capron D; Dedeurwaerder S; Zawadzki P; Morel V; Wychowski C; Duverlie G
    J Med Virol; 2007 Feb; 79(2):144-54. PubMed ID: 17177298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.
    Forns X; García-Retortillo M; Serrano T; Feliu A; Suarez F; de la Mata M; García-Valdecasas JC; Navasa M; Rimola A; Rodés J
    J Hepatol; 2003 Sep; 39(3):389-96. PubMed ID: 12927925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
    Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
    J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.
    Ali I; Khan S; Attaullah S; Khan SN; Khan J; Siraj S; Iqbal A; Swati ZA; Idrees M
    Virol J; 2011 May; 8():258. PubMed ID: 21609495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.
    Thomas RM; Brems JJ; Guzman-Hartman G; Yong S; Cavaliere P; Van Thiel DH
    Liver Transpl; 2003 Sep; 9(9):905-15. PubMed ID: 12942451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.
    Lee JH; von Wagner M; Roth WK; Teuber G; Sarrazin C; Zeuzem S
    J Hepatol; 1998 Jul; 29(1):29-35. PubMed ID: 9696489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
    J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Response to interferon therapy using mutations in the HCV-NS5A].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2011 May; 69 Suppl 4():234-8. PubMed ID: 22096925
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Pawlotsky JM
    Curr Gastroenterol Rep; 2013 Feb; 15(2):309. PubMed ID: 23314805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
    He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.